Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma

被引：12

作者：

Trudel, Suzanne ^{[1
]}

McCurdy, Arleigh ^{[2
]}

Fu, Molei ^{[3
]}

Sutherland, Heather J. ^{[4
]}

Louzada, Martha L. ^{[5
]}

Chu, Michael P. ^{[6
]}

White, Darrell J. ^{[7
,8
]}

Mian, Hira S. ^{[9
]}

Kotb, Rami ^{[10
]}

Othman, Ibraheem ^{[11
]}

Kardjadj, Moustafa ^{[12
]}

Gul, Engin ^{[13
]}

Reece, Donna E. ^{[3
]}

机构：

[1] Princess Margaret Canc Ctr, Dept Med Oncol & Hematol, Toronto, ON, Canada

[2] Ottawa Hosp, Dept Med, Div Hematol, Ottawa, ON, Canada

[3] Canadian Myeloma Res Grp CMRG, Vaughan, ON, Canada

[4] Vancouver Gen Hosp, Div Hematol, Vancouver, BC, Canada

[5] Univ Western Ontario, London Hlth Sci Ctr, London, ON, Canada

[6] Cross Canc Inst, Dept Oncol, Edmonton, AB, Canada

[7] Dalhousie Univ, Halifax, NS, Canada

[8] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada

[9] McMaster Univ, Dept Oncol, Hamilton, ON, Canada

[10] CancerCare Manitoba, Dept Med Oncol & Hematol, Winnipeg, MB, Canada

[11] Saskatchewan Canc Agcy, Allan Blair Canc Ctr, Regina, SK, Canada

[12] Canadian Myeloma Res Grp, Toronto, ON, Canada

[13] Canadian Myeloma Res Grp CMRG, Concord, ON, Canada

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-160445

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：7306 / 7307

页数：2

共 50 条

[1] Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial
Mccurdy, Arleigh
Reece, Donna
Louzada, Martha L.
White, Darrell
Parkin, Stephen
Chu, Michael P.
Kotb, Rami
Mian, Hira
Othman, Ibraheem
Su, Jiandong
Khan, Aniba
Gul, Engin
Trudel, Suzanne
BLOOD CANCER JOURNAL, 2024, 14 (01):
[2] Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma
Dimopoulos, Meletios Athanasios
Beksac, Meral
Pour, Ludek
Delimpasi, Sosana
Vorobyev, Vladimir
Quach, Hang
Spicka, Ivan
Radocha, Jakub
Robak, Pawel
Kim, Kihyun
Cavo, Michele
Suzuki, Kazuhito
Morris, Kristin
Pompilus, Farrah
Phillips-Jones, Amy
Zhou, Xiaoou L.
Fulci, Giulia
Sule, Neal
Kremer, Brandon E.
Opalinska, Joanna
Mateos, Maria-Victoria
Trudel, Suzanne
NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (05): : 408 - 421
[3] Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial
Suzanne Trudel
Arleigh McCurdy
Martha L. Louzada
Stephen Parkin
Darrell White
Michael P. Chu
Rami Kotb
Hira Mian
Ibraheem Othman
Jiandong Su
Aniba Khan
Engin Gul
Donna Reece
Nature Medicine, 2024, 30 : 543 - 551
[4] Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial
Trudel, Suzanne
Mccurdy, Arleigh
Louzada, Martha L.
Parkin, Stephen
White, Darrell
Chu, Michael P.
Kotb, Rami
Mian, Hira
Othman, Ibraheem
Su, Jiandong
Khan, Aniba
Gul, Engin
Reece, Donna
NATURE MEDICINE, 2024, 30 (02) : 543 - 551
[5] Belantamab in Combination with Dexamethasone in Patients with Triple-class Relapsed/Refractory Multiple Myeloma
Atieh, Tahani
Atrash, Shebli
Ahmed, Nausheen
Mohan, Meera
Cui, Wei
Shune, Leyla
Hajjar, Susana
Mahmoudjafari, Zahra
Quick, Julie
Wishna, Anne
Riffel, Justin
McGuirk, Joseph
Mohyuddin, Ghulam Rehman
Abdallah, Al-Ola
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (12): : 912 - 919
[6] Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma
Mateos, Maria Victoria
Weisel, Katja
Terpos, Evangelos
Delimpasi, Sossana
Kastritis, Efstathios
Zamagni, Elena
Delforge, Michel
Ocio, Enrique
Katodritou, Eirini
Gay, Francesca
Larocca, Alessandra
Leleu, Xavier
Otero, Paula Rodriguez
Schjesvold, Fredik
Cavo, Michele
Dimopoulos, Meletios A.
HAEMATOLOGICA, 2024, 109 (07) : 2337 - 2340
[7] Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma
Mateos, Maria Victoria
Weisel, Katja
Terpos, Evangelos
Delimpasi, Sossana
Kastritis, Efstathios
Zamagni, Elena
Delforge, Michel
Ocio, Enrique
Katodritou, Eirini
Gay, Francesca
Larocca, Alessandra
Leleu, Xavier
Otero, Paula Rodriguez
Schjesvold, Fredik
Cavo, Michele
Dimopoulos, Meletios A.
REVISTA CHILENA DE LITERATURA, 2024, (109): : 2337 - 2340
[8] Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
Hungria, Vania
Robak, Pawel
Hus, Marek
Zherebtsova, Vera
Ward, Christopher
Ho, P. Joy
Ribas de Almeida, Ana Carolina
Hajek, Roman
Kim, Kihyun
Grosicki, Sebastian
Sia, Hanlon
Bryant, Adam
Pitombeira de Lacerda, Marcelo
Aparecida Martinez, Gracia
Sureda Balari, Anna Maria
Sandhu, Irwindeep
Cerchione, Claudio
Ganly, Peter
Dimopoulos, Meletios
Fu, Chengcheng
Garg, Mamta
Abdallah, Al-Ola
Oriol, Albert
Gatt, Moshe E.
Cavo, Michele
Rifkin, Robert
Fujisaki, Tomoaki
Mielnik, Michal
Pirooz, Nick
Mckeown, Astrid
Mcnamara, Simon
Zhou, Xiangdong
Nichols, Maureen
Lewis, Eric
Rogers, Rachel
Baig, Hena
Eccersley, Lydia
Roy-Ghanta, Sumita
Opalinska, Joanna
Mateos, Maria-Victoria
NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (05): : 393 - 407
[9] Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
Lucijanic, Marko
Sabljic, Anica
Krecak, Ivan
NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (14): : 1364 - 1365
[10] Part 1 Results of a Dose-Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)
Trudel, Suzanne
McCurdy, Arleigh
Sutherland, Heather J.
Louzada, Martha L.
Venner, Christopher P.
Mian, Hira S.
Kotb, Rami
Othman, Ibraheem
Camacho, Fernando
Gul, Engin
Reece, Donna E.
White, Darrell J.
Fu, Molei
BLOOD, 2021, 138

← 1 2 3 4 5 →